Artgen's net profit under IFRS for 6 months of 2025 amounted to ₽132.43 million, an increase of 27.9% compared to ₽103.58 million in the previous year. Revenue increased by 12.6% to ₽838.87 million against ₽745.12 million a year earlier.

Artgen's RAS net profit for 6 months of 2025 amounted to ₽44.7 million, a 2.5-fold decrease from ₽113.2 million in the previous year. Revenue increased by 15.6% to ₽74.3 million from ₽64.3 million a year earlier.

RBT and the Almazov Center have signed an agreement on cooperation in research and development activities in order to develop and implement innovative medical technologies and products in practical healthcare. As part of the agreement, the parties planned to develop and market solutions for organ preservation, targeted drug delivery systems, drugs for the tr...

Artgen's net profit by RAS for the first 3 months of 2025 was ₽29.6 million, down 56.9% from ₽68.7 million in the previous year. Revenue increased 33.3% to ₽45.07 million from ₽33.8 million a year earlier.